You are here
The content on this page and other TGA archive pages is provided to assist research and may contain references to activities or policies that have no current application. See the full archive disclaimer.
Provisional approval pathway - first determination decision
Olaratumab(rmc) LARTRUVO is the first medicine to be granted a provisional approval determination under the new provisional approval pathway which came into effect on 20 March 2018. LARTRUVO was also granted an orphan drug designation for the treatment of soft tissue sarcoma on 9 February 2018.
Details of prescription medicines that have an approved provisional determination, priority review determination or orphan drug designation are published on the TGA website: Prescription medicines determination and designation notices.